External Quality Assessment of Factor VIII Inhibitor Assays

Roslyn A. Bonar; Emmanuel J. Favaloro; Katherine Marsden

doi:10.1055/s-0033-1334464

Seminars in Thrombosis and Hemostasis, Inhaltsverzeichnis

Semin Thromb Hemost 2013; 39(03): 320-326
DOI: 10.1055/s-0033-1334464

Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

External Quality Assessment of Factor VIII Inhibitor Assays

Roslyn A. Bonar

¹RCPAQAP Haematology, St Leonards, New South Wales, Australia

,

Emmanuel J. Favaloro

²Department of Haematology, Institute of Clinical Pathology and Medical Research (ICPMR), Pathology West, Westmead Hospital, New South Wales, Australia

,

Katherine Marsden

³Department of Pathology, Royal Hobart Hospital, Hobart, Australia

› Institutsangaben

Abstract

Inhibitors to coagulation factors cause prolongation of routine hemostasis laboratory test results and have clinical relevance in the management of congenital and acquired hemophilia patients. Factor VIII (FVIII) inhibitors can be either allo-antibodies (in hemophilia A) or auto-antibodies (in acquired hemophilia) directed against FVIII. The most commonly used assays for detecting these inhibitors are the classical Bethesda assay or a modified (Nijmegen) method. Previous laboratory assessments from the Royal College of Pathologists of Australia Quality Assurance Program (RCPAQAP) Haematology and other external quality assessment programs have shown wide variability in FVIII inhibitor results and method performance, as well as a significant degree of false-positive and false-negative interpretations. Despite its limitations, the Bethesda assay is still the primary assay used in laboratories for detecting the presence and strength of a FVIII inhibitor. Therefore, it is of utmost importance that this assay is performed well. The current report reviews the most recent findings from the RCPAQAP Haematology, which show there is still a need for better standardization and improvement in the detection of low-level FVIII inhibitors to ultimately provide better clinical management of affected patients.

Keywords

factor VIII (FVIII) inhibitor - Bethesda - Nijmegen - external quality assessment/assurance (EQA) - proficiency testing

Volltext

Referenzen

References
1 Favaloro EJ, Bonar R, Duncan E , et al. Mis-identification of factor inhibitors by diagnostic haemostasis laboratories: recognition of pitfalls and elucidation of strategies. A follow up to a large multicentre evaluation. Pathology 2007; 39 (5) 504-511
2 Favaloro EJ, Bonar R, Kershaw G, Duncan E, Sioufi J, Marsden K. Investigations from external quality assurance programs reveal a high degree of variation in the laboratory identification of coagulation factor inhibitors. Semin Thromb Hemost 2009; 35 (8) 794-805
3 Franchini M, Lippi G, Favaloro EJ. Acquired inhibitors of coagulation factors: part II. Semin Thromb Hemost 2012; 38 (5) 447-453
4 Coppola A, Favaloro EJ, Tufano A, Di Minno MN, Cerbone AM, Franchini M. Acquired inhibitors of coagulation factors: part I-acquired hemophilia A. Semin Thromb Hemost 2012; 38 (5) 433-446
5 Bonar R, Favaloro EJ, Adcock D. Quality in coagulation and haemostasis testing. Biochem Med (Zagreb) 2010; 20 (2) 184-199
6 Kitchen S, Iampietro R, Woolley AM, Preston FE. Anti Xa monitoring during treatment with low molecular weight heparin or danaparoid: inter-assay variability. Thromb Haemost 1999; 82 (4) 1289-1293
7 Cuker A, Raby A, Moffat KA, Flynn G, Crowther MA. Interlaboratory variation in heparin monitoring: Lessons from the Quality Management Program of Ontario coagulation surveys. Thromb Haemost 2010; 104 (4) 837-844
8 Favaloro EJ, Bonar R, Chapman K, Meiring M, Funk Adcock D. Differential sensitivity of von Willebrand factor (VWF) 'activity' assays to large and small VWF molecular weight forms: a cross-laboratory study comparing ristocetin cofactor, collagen-binding and mAb-based assays. J Thromb Haemost 2012; 10 (6) 1043-1054
9 Favaloro EJ. Von Willebrand factor assay proficiency testing continued. Am J Clin Pathol 2011; 136 (4) 657-659
10 Chandler WL, Peerschke EI, Castellone DD, Meijer P. NASCOLA Proficiency Testing Committee. Von Willebrand factor assay proficiency testing. The North American Specialized Coagulation Laboratory Association experience. Am J Clin Pathol 2011; 135 (6) 862-869
11 Kitchen S, Jennings I, Preston FE, Kitchen DP, Woods TA, Walker ID. Interlaboratory variation in factor VIII:C inhibitor assay results is sufficient to influence patient management: data from the UK national quality external assessment scheme for blood coagulation. Semin Thromb Hemost 2009; 35 (8) 778-785
12 Meijer P, Verbruggen B. The between-laboratory variation of factor VIII inhibitor testing: the experience of the external quality assessment program of the ECAT foundation. Semin Thromb Hemost 2009; 35 (8) 786-793
13 Kershaw G, Jayakodi D, Dunkley S. Laboratory identification of factor inhibitors: the perspective of a large tertiary hemophilia center. Semin Thromb Hemost 2009; 35 (8) 760-768
14 Verbruggen B. Diagnosis and quantification of factor VIII inhibitors. Haemophilia 2010; 16 (102) 20-24
15 Favaloro EJ, Bonar R, Duncan E , et al; RCPA QAP in Haematology Haemostasis Committee. Identification of factor inhibitors by diagnostic haemostasis laboratories: a large multi-centre evaluation. Thromb Haemost 2006; 96 (1) 73-78
16 Kasper CK, Aledort LM, Counts RB , et al. Letter: a more uniform measurement of factor VIII inhibitors. Thromb Diath Haemorrh 1975; 34 (3) 869-872
17 Verbruggen B, Novakova I, Wessels H, Boezeman J, van den Berg M, Mauser-Bunschoten E. The Nijmegen modification of the Bethesda assay for factor VIII:C inhibitors: improved specificity and reliability. Thromb Haemost 1995; 73 (2) 247-251
18 Favaloro EJ, Bonar R, Kershaw G, Mohammed S, Duncan E, Marsden K. RCPA Haematology QAP Haemostasis Committee. Laboratory identification of factor VIII inhibitors in the real world: the experience from Australasia. Haemophilia 2010; 16 (4) 662-670
19 Ma AD, Carrizosa D. Acquired Factor VIII Inhibitors: Pathophysiology and Treatment. Hematology Am Soc Hematol Educ Program 2006; 432-437
20 Verbruggen B, van Heerde WL, Laros-van Gorkom BA. Improvements in factor VIII inhibitor detection: From Bethesda to Nijmegen. Semin Thromb Hemost 2009; 35 (8) 752-759
21 Peerschke EI, Castellone DD, Ledford-Kraemer M, Van Cott EM, Meijer P. NASCOLA Proficiency Testing Committee. Laboratory assessment of factor VIII inhibitor titer: the North American Specialized Coagulation Laboratory Association experience. Am J Clin Pathol 2009; 131 (4) 552-558
22 Inhibitor Exercise Part 2 2007. Available at: http://www.rcpaqap.com.au/haematology/educational/uploadedfiles/Inexp22007.pdf . Accessed December 10, 2012
23 Inhibitor Exercise 2009. Available at: http://www.rcpaqap.com.au/haematology/educational/uploadedfiles/FVIIIFINAL.pdf . Accessed December 10, 2012
24 Verbruggen B, van Heerde W, Novákovà I, Lillicrap D, Giles A. A 4% solution of bovine serum albumin may be used in place of factor VIII:C deficient plasma in the control sample in the Nijmegen modification of the Bethesda factor VIII:C inhibitor assay. Thromb Haemost 2002; 88 (2) 362-364
25 Verbruggen B, Dardikh M, Polenewen R, van Duren C, Meijer P. The factor VIII inhibitor assays can be standardized: results of a workshop. J Thromb Haemost 2011; 9 (10) 2003-2008
26 Giles AR, Verbruggen B, Rivard GE, Teitel J, Walker I. Association of Hemophilia Centre Directors of Canada. Factor VIII/IX Subcommittee of Scientific and Standardization Committee of International Society on Thrombosis and Haemostasis. A detailed comparison of the performance of the standard versus the Nijmegen modification of the Bethesda assay in detecting factor VIII:C inhibitors in the haemophilia A population of Canada. Thromb Haemost 1998; 79 (4) 872-875